Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort
Summary Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first‐line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2015-02, Vol.22 (2), p.120-127 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 2 |
| container_start_page | 120 |
| container_title | Journal of viral hepatitis |
| container_volume | 22 |
| creator | Papatheodoridis, G. V. Manolakopoulos, S. Touloumi, G. Nikolopoulou, G. Raptopoulou-Gigi, M. Gogos, C. Vafiadis-Zouboulis, I. Karamanolis, D. Chouta, A. Ilias, A. Drakoulis, C. Mimidis, K. Ketikoglou, I. Manesis, E. Mela, M. Hatzis, G. Dalekos, G. N. |
| description | Summary
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first‐line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg‐negative CHB patients treated with entecavir. HBeAg‐negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0–4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P |
| doi_str_mv | 10.1111/jvh.12283 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652404798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1652404798</sourcerecordid><originalsourceid>FETCH-LOGICAL-i4923-df8c30285acb3fdebf89e0049b3fa159cc6f05b56087750894574249344479153</originalsourceid><addsrcrecordid>eNpdkc1uEzEUhS0EoqWw4AWQJTZsJvXvjIddWyABVUWI0LCzHOdOx-lkHGxPSp-DF8aTlC7w5h7b37m27kHoNSUTmtfpetdOKGOKP0HHlJeyYKrmT0ctWUEkEUfoRYxrQihnkj5HRyyfkVLJY_RnBluTvIWuGzoTsDXBut5vDA4u3mLX49k5nN0UPdyY5HaAbRt87yxuR59LLuJzPCroU8R3LrXYh331Q8LWhdD6mKEUwCRYHYjMgjU7F97j_PwVpMk0ANjc3Lc-pJfoWWO6CK8e6gn68enj_GJWXH6dfr44uyycqBkvVo2ynDAljV3yZgXLRtVAiKjzzlBZW1s2RC5lSVRVSaJqISvBRM2FEFVNJT9B7w59t8H_GiAmvXFxnITpwQ9R01IyQTKrMvr2P3Tth9Dn32VKlFxKuqfePFDDcgMrvQ1uY8K9_jfuDJwegDvXwf3jPSV6zFHnHPU-R_3lerYX2VEcHC4m-P3oMOFWlxWvpF5cTfXPb4vr74v5XH_gfwGFsp_q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1646355198</pqid></control><display><type>article</type><title>Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Papatheodoridis, G. V. ; Manolakopoulos, S. ; Touloumi, G. ; Nikolopoulou, G. ; Raptopoulou-Gigi, M. ; Gogos, C. ; Vafiadis-Zouboulis, I. ; Karamanolis, D. ; Chouta, A. ; Ilias, A. ; Drakoulis, C. ; Mimidis, K. ; Ketikoglou, I. ; Manesis, E. ; Mela, M. ; Hatzis, G. ; Dalekos, G. N.</creator><creatorcontrib>Papatheodoridis, G. V. ; Manolakopoulos, S. ; Touloumi, G. ; Nikolopoulou, G. ; Raptopoulou-Gigi, M. ; Gogos, C. ; Vafiadis-Zouboulis, I. ; Karamanolis, D. ; Chouta, A. ; Ilias, A. ; Drakoulis, C. ; Mimidis, K. ; Ketikoglou, I. ; Manesis, E. ; Mela, M. ; Hatzis, G. ; Dalekos, G. N. ; HepNet.Greece Study Group</creatorcontrib><description>Summary
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first‐line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg‐negative CHB patients treated with entecavir. HBeAg‐negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0–4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial agent. In conclusion, our large nationwide study indicates that the HCC risk remains increased in entecavir‐treated HBeAg‐negative CHB patients with cirrhosis, particularly of older age, at least for the first 5 years. The HCC risk does not seem to be significantly reduced with entecavir compared with antiviral therapy starting with lamivudine.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/jvh.12283</identifier><identifier>PMID: 25040685</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Carcinoma, Hepatocellular - epidemiology ; cirrhosis ; Cohort Studies ; entecavir ; Female ; Greece - epidemiology ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; hepatitis B ; Hepatitis B e Antigens - blood ; Hepatitis B, Chronic - complications ; Hepatitis B, Chronic - drug therapy ; hepatocellular carcinoma ; Humans ; Incidence ; lamivudine ; Lamivudine - therapeutic use ; Liver Neoplasms - epidemiology ; Male ; Middle Aged ; Prospective Studies ; Risk Assessment ; Treatment Outcome</subject><ispartof>Journal of viral hepatitis, 2015-02, Vol.22 (2), p.120-127</ispartof><rights>2014 John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons Ltd.</rights><rights>Copyright © 2015 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvh.12283$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvh.12283$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25040685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papatheodoridis, G. V.</creatorcontrib><creatorcontrib>Manolakopoulos, S.</creatorcontrib><creatorcontrib>Touloumi, G.</creatorcontrib><creatorcontrib>Nikolopoulou, G.</creatorcontrib><creatorcontrib>Raptopoulou-Gigi, M.</creatorcontrib><creatorcontrib>Gogos, C.</creatorcontrib><creatorcontrib>Vafiadis-Zouboulis, I.</creatorcontrib><creatorcontrib>Karamanolis, D.</creatorcontrib><creatorcontrib>Chouta, A.</creatorcontrib><creatorcontrib>Ilias, A.</creatorcontrib><creatorcontrib>Drakoulis, C.</creatorcontrib><creatorcontrib>Mimidis, K.</creatorcontrib><creatorcontrib>Ketikoglou, I.</creatorcontrib><creatorcontrib>Manesis, E.</creatorcontrib><creatorcontrib>Mela, M.</creatorcontrib><creatorcontrib>Hatzis, G.</creatorcontrib><creatorcontrib>Dalekos, G. N.</creatorcontrib><creatorcontrib>HepNet.Greece Study Group</creatorcontrib><title>Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Summary
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first‐line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg‐negative CHB patients treated with entecavir. HBeAg‐negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0–4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial agent. In conclusion, our large nationwide study indicates that the HCC risk remains increased in entecavir‐treated HBeAg‐negative CHB patients with cirrhosis, particularly of older age, at least for the first 5 years. The HCC risk does not seem to be significantly reduced with entecavir compared with antiviral therapy starting with lamivudine.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>cirrhosis</subject><subject>Cohort Studies</subject><subject>entecavir</subject><subject>Female</subject><subject>Greece - epidemiology</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>hepatitis B</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B, Chronic - complications</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>hepatocellular carcinoma</subject><subject>Humans</subject><subject>Incidence</subject><subject>lamivudine</subject><subject>Lamivudine - therapeutic use</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Risk Assessment</subject><subject>Treatment Outcome</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1uEzEUhS0EoqWw4AWQJTZsJvXvjIddWyABVUWI0LCzHOdOx-lkHGxPSp-DF8aTlC7w5h7b37m27kHoNSUTmtfpetdOKGOKP0HHlJeyYKrmT0ctWUEkEUfoRYxrQihnkj5HRyyfkVLJY_RnBluTvIWuGzoTsDXBut5vDA4u3mLX49k5nN0UPdyY5HaAbRt87yxuR59LLuJzPCroU8R3LrXYh331Q8LWhdD6mKEUwCRYHYjMgjU7F97j_PwVpMk0ANjc3Lc-pJfoWWO6CK8e6gn68enj_GJWXH6dfr44uyycqBkvVo2ynDAljV3yZgXLRtVAiKjzzlBZW1s2RC5lSVRVSaJqISvBRM2FEFVNJT9B7w59t8H_GiAmvXFxnITpwQ9R01IyQTKrMvr2P3Tth9Dn32VKlFxKuqfePFDDcgMrvQ1uY8K9_jfuDJwegDvXwf3jPSV6zFHnHPU-R_3lerYX2VEcHC4m-P3oMOFWlxWvpF5cTfXPb4vr74v5XH_gfwGFsp_q</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Papatheodoridis, G. V.</creator><creator>Manolakopoulos, S.</creator><creator>Touloumi, G.</creator><creator>Nikolopoulou, G.</creator><creator>Raptopoulou-Gigi, M.</creator><creator>Gogos, C.</creator><creator>Vafiadis-Zouboulis, I.</creator><creator>Karamanolis, D.</creator><creator>Chouta, A.</creator><creator>Ilias, A.</creator><creator>Drakoulis, C.</creator><creator>Mimidis, K.</creator><creator>Ketikoglou, I.</creator><creator>Manesis, E.</creator><creator>Mela, M.</creator><creator>Hatzis, G.</creator><creator>Dalekos, G. N.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201502</creationdate><title>Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort</title><author>Papatheodoridis, G. V. ; Manolakopoulos, S. ; Touloumi, G. ; Nikolopoulou, G. ; Raptopoulou-Gigi, M. ; Gogos, C. ; Vafiadis-Zouboulis, I. ; Karamanolis, D. ; Chouta, A. ; Ilias, A. ; Drakoulis, C. ; Mimidis, K. ; Ketikoglou, I. ; Manesis, E. ; Mela, M. ; Hatzis, G. ; Dalekos, G. N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i4923-df8c30285acb3fdebf89e0049b3fa159cc6f05b56087750894574249344479153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>cirrhosis</topic><topic>Cohort Studies</topic><topic>entecavir</topic><topic>Female</topic><topic>Greece - epidemiology</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>hepatitis B</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B, Chronic - complications</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>hepatocellular carcinoma</topic><topic>Humans</topic><topic>Incidence</topic><topic>lamivudine</topic><topic>Lamivudine - therapeutic use</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Risk Assessment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papatheodoridis, G. V.</creatorcontrib><creatorcontrib>Manolakopoulos, S.</creatorcontrib><creatorcontrib>Touloumi, G.</creatorcontrib><creatorcontrib>Nikolopoulou, G.</creatorcontrib><creatorcontrib>Raptopoulou-Gigi, M.</creatorcontrib><creatorcontrib>Gogos, C.</creatorcontrib><creatorcontrib>Vafiadis-Zouboulis, I.</creatorcontrib><creatorcontrib>Karamanolis, D.</creatorcontrib><creatorcontrib>Chouta, A.</creatorcontrib><creatorcontrib>Ilias, A.</creatorcontrib><creatorcontrib>Drakoulis, C.</creatorcontrib><creatorcontrib>Mimidis, K.</creatorcontrib><creatorcontrib>Ketikoglou, I.</creatorcontrib><creatorcontrib>Manesis, E.</creatorcontrib><creatorcontrib>Mela, M.</creatorcontrib><creatorcontrib>Hatzis, G.</creatorcontrib><creatorcontrib>Dalekos, G. N.</creatorcontrib><creatorcontrib>HepNet.Greece Study Group</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papatheodoridis, G. V.</au><au>Manolakopoulos, S.</au><au>Touloumi, G.</au><au>Nikolopoulou, G.</au><au>Raptopoulou-Gigi, M.</au><au>Gogos, C.</au><au>Vafiadis-Zouboulis, I.</au><au>Karamanolis, D.</au><au>Chouta, A.</au><au>Ilias, A.</au><au>Drakoulis, C.</au><au>Mimidis, K.</au><au>Ketikoglou, I.</au><au>Manesis, E.</au><au>Mela, M.</au><au>Hatzis, G.</au><au>Dalekos, G. N.</au><aucorp>HepNet.Greece Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2015-02</date><risdate>2015</risdate><volume>22</volume><issue>2</issue><spage>120</spage><epage>127</epage><pages>120-127</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Summary
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first‐line antivirals remains uncertain. We estimated the incidence and evaluated predictors of HCC in a large nationwide prospective cohort (HepNet.Greece) of HBeAg‐negative CHB patients treated with entecavir. HBeAg‐negative CHB patients from the same cohort who were initially treated with lamivudine were used as controls. We included 321 patients treated with entecavir for a median of 40 months and 818 patients treated initially with lamivudine for a median of 60 months. In the entecavir group, HCC developed in 4 of 321 (1.2%) patients at a median of 1.5 (range: 1.0–4.5) years, while the cumulative HCC incidence was significantly higher in cirrhotics than noncirrhotics (1, 3, 5 years: 0%, 3%, 9% vs 1%, 1%, 1%; P = 0.024) and in older patients (P = 0.026). Entecavir compared with lamivudine group patients had lower HCC incidence (1, 3, 5 years: 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6%; P = 0.024). However, in multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial agent. In conclusion, our large nationwide study indicates that the HCC risk remains increased in entecavir‐treated HBeAg‐negative CHB patients with cirrhosis, particularly of older age, at least for the first 5 years. The HCC risk does not seem to be significantly reduced with entecavir compared with antiviral therapy starting with lamivudine.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25040685</pmid><doi>10.1111/jvh.12283</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2015-02, Vol.22 (2), p.120-127 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652404798 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - epidemiology cirrhosis Cohort Studies entecavir Female Greece - epidemiology Guanine - analogs & derivatives Guanine - therapeutic use hepatitis B Hepatitis B e Antigens - blood Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy hepatocellular carcinoma Humans Incidence lamivudine Lamivudine - therapeutic use Liver Neoplasms - epidemiology Male Middle Aged Prospective Studies Risk Assessment Treatment Outcome |
| title | Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatocellular%20carcinoma%20risk%20in%20HBeAg-negative%20chronic%20hepatitis%20B%20patients%20with%20or%20without%20cirrhosis%20treated%20with%20entecavir:%20HepNet.Greece%20cohort&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Papatheodoridis,%20G.%20V.&rft.aucorp=HepNet.Greece%20Study%20Group&rft.date=2015-02&rft.volume=22&rft.issue=2&rft.spage=120&rft.epage=127&rft.pages=120-127&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/jvh.12283&rft_dat=%3Cproquest_pubme%3E1652404798%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1646355198&rft_id=info:pmid/25040685&rfr_iscdi=true |